Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients.

Mouliere F, Mair R, Chandrananda D, Marass F, Smith CG, Su J, Morris J, Watts C, Brindle KM, Rosenfeld N.

EMBO Mol Med. 2018 Nov 6. pii: e9323. doi: 10.15252/emmm.201809323. [Epub ahead of print]

3.

Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models.

Mair R, Mouliere F, Smith CG, Chandrananda D, Gale D, Marass F, Tsui DWY, Massie CE, Wright AJ, Watts C, Rosenfeld N, Brindle KM.

Cancer Res. 2018 Nov 2. pii: canres.0074.2018. doi: 10.1158/0008-5472.CAN-18-0074. [Epub ahead of print]

PMID:
30389699
4.

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.

Risberg B, Tsui DWY, Biggs H, Ruiz-Valdepenas Martin de Almagro A, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, Marass F, Chandrananda D, Moore E, Morris J, Plagnol V, Rosenfeld N, Caldas C, Brenton JD, Gale D.

J Mol Diagn. 2018 Nov;20(6):883-892. doi: 10.1016/j.jmoldx.2018.07.005. Epub 2018 Aug 28.

5.

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, Chandrananda D, Soo RA, Lim HL, Goh BC, Caldas C, Forshew T, Gale D, Liu W, Morris J, Marass F, Eisen T, Chin TM, Rosenfeld N.

EMBO Mol Med. 2018 Jun;10(6). pii: e7945. doi: 10.15252/emmm.201707945.

6.

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.

Patel KM, van der Vos KE, Smith CG, Mouliere F, Tsui D, Morris J, Chandrananda D, Marass F, van den Broek D, Neal DE, Gnanapragasam VJ, Forshew T, van Rhijn BW, Massie CE, Rosenfeld N, van der Heijden MS.

Sci Rep. 2017 Jul 17;7(1):5554. doi: 10.1038/s41598-017-05623-3.

7.

CVE: an R package for interactive variant prioritisation in precision oncology.

Mock A, Murphy S, Morris J, Marass F, Rosenfeld N, Massie C.

BMC Med Genomics. 2017 May 25;10(1):37. doi: 10.1186/s12920-017-0261-6.

8.

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD.

J Pathol Clin Res. 2016 Jul 13;2(4):247-258. eCollection 2016 Oct.

9.

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, Farahani H, Shumansky K, Kingsbury Z, Humphray S, Bentley D, Shah SP, Wallis M, Rosenfeld N, Caldas C.

Nat Commun. 2015 Nov 4;6:8760. doi: 10.1038/ncomms9760.

10.

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.

Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, Alexandrov LB, Sloggett C, Cmero M, Marass F, Tsui D, Mangiola S, Lonie A, Naeem H, Sapre N, Phal PM, Kurganovs N, Chin X, Kerger M, Warren AY, Neal D, Gnanapragasam V, Rosenfeld N, Pedersen JS, Ryan A, Haviv I, Costello AJ, Corcoran NM, Hovens CM.

Nat Commun. 2015 Apr 1;6:6605. doi: 10.1038/ncomms7605.

11.

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, Dunham A, May AP, Rosenfeld N, Forshew T, Eisen T.

Genes Chromosomes Cancer. 2014 Jan;53(1):38-51. doi: 10.1002/gcc.22116. Epub 2013 Oct 29.

PMID:
24166983
12.

Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension.

Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Küsters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ.

Nat Genet. 2013 Sep;45(9):1055-60. doi: 10.1038/ng.2716. Epub 2013 Aug 4.

PMID:
23913004
13.

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N.

Nature. 2013 May 2;497(7447):108-12. doi: 10.1038/nature12065. Epub 2013 Apr 7.

PMID:
23563269
14.

JaPaFi: A Novel Program for the Identification of Highly Conserved DNA Sequences.

Sadeque A, Barsky M, Marass F, Kruczkiewicz P, Upton C.

Viruses. 2010 Sep;2(9):1867-85. doi: 10.3390/v2091867. Epub 2010 Aug 31.

15.

A 44K microarray dataset of the changing transcriptome in developing Atlantic salmon (Salmo salar L.).

Jantzen SG, Sanderson DS, von Schalburg KR, Yasuike M, Marass F, Koop BF.

BMC Res Notes. 2011 Mar 29;4:88. doi: 10.1186/1756-0500-4-88.

16.
17.

Supplemental Content

Loading ...
Support Center